A Polyclonal Antibody against a Burkholderia cenocepacia OmpA-like Protein Strongly Impairs Pseudomonas aeruginosa and B. multivorans Virulence

Despite advances in therapies, bacterial chronic respiratory infections persist as life-threatening to patients suffering from cystic fibrosis (CF). Pseudomonas aeruginosa and bacteria of the Burkholderia cepacia complex are among the most difficult of these infections to treat, due to factors like their resistance to multiple antibiotics and ability to form biofilms. The lack of effective antimicrobial strategies prompted our search for alternative immunotherapies that can effectively control and reduce those infections among CF patients. Previous work from our group showed that the anti-BCAL2645 goat polyclonal antibody strongly inhibited Burkholderia cenocepacia to adhere and invade cultured epithelial cells. In this work, we showed that the polyclonal antibody anti-BCAL2645 also strongly inhibited the ability of P. aeruginosa to form biofilms, and to adhere and invade the human bronchial epithelial cell line CFBE41o-. The polyclonal antibody also inhibited, to a lesser extent, the ability of B. multivorans to adhere and invade the human bronchial epithelial cell line CFBE41o. We also show that the ability of B. cenocepacia, P. aeruginosa and B. multivorans to kill larvae of the Galleria mellonella model of infection was impaired when bacteria were incubated with the anti-BCAL2645 antibody prior to the infection. Our findings show that an antibody against BCAL2645 possesses a significant potential for the development of new immunotherapies against these three important bacterial species capable of causing devastating and often lethal infections among CF patients.

[1]  S. Sousa,et al.  Antibody-Based Immunotherapies as a Tool for Tackling Multidrug-Resistant Bacterial Infections , 2022, Vaccines.

[2]  A. Garratt,et al.  Worldwide rates of diagnosis and effective treatment for cystic fibrosis. , 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3]  S. Sousa,et al.  A Polyclonal Antibody Raised against the Burkholderia cenocepacia OmpA-like Protein BCAL2645 Impairs the Bacterium Adhesion and Invasion of Human Epithelial Cells In Vitro , 2021, Biomedicines.

[4]  S. Sousa,et al.  Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections , 2021, Vaccines.

[5]  Andreia I. Pimenta,et al.  Burkholderia cenocepacia BCAM2418‐induced antibody inhibits bacterial adhesion, confers protection to infection and enables identification of host glycans as adhesin targets , 2021, Cellular microbiology.

[6]  S. Sousa,et al.  Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome , 2020, Vaccines.

[7]  E. Torrents,et al.  Differential adaptability between reference strains and clinical isolates of Pseudomonas aeruginosa into the lung epithelium intracellular lifestyle , 2020, Virulence.

[8]  C. Sen,et al.  Anti-Psl Targeting of Pseudomonas aeruginosa Biofilms for Neutrophil-Mediated Disruption , 2017, Scientific Reports.

[9]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..

[10]  E. Giralt,et al.  Combating virulence of Gram-negative bacilli by OmpA inhibition , 2017, Scientific Reports.

[11]  L. Chiarelli,et al.  Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches , 2017, Front. Microbiol..

[12]  Bjoern Peters,et al.  BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes , 2017, Nucleic Acids Res..

[13]  V. Cooper,et al.  Long-Term Evolution of Burkholderia multivorans during a Chronic Cystic Fibrosis Infection Reveals Shifting Forces of Selection , 2016, mSystems.

[14]  G. O’Toole,et al.  Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat , 2015, PLoS pathogens.

[15]  Raymond Lo,et al.  Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database , 2015, Nucleic Acids Res..

[16]  M. Valvano.  Intracellular survival of Burkholderia cepacia complex in phagocytic cells. , 2015, Canadian journal of microbiology.

[17]  S. McClean,et al.  The Tyrosine Kinase BceF and the Phosphotyrosine Phosphatase BceD of Burkholderia contaminans Are Required for Efficient Invasion and Epithelial Disruption of a Cystic Fibrosis Lung Epithelial Cell Line , 2014, Infection and Immunity.

[18]  P. Gilligan,et al.  Localization of Burkholderia cepacia Complex Bacteria in Cystic Fibrosis Lungs and Interactions with Pseudomonas aeruginosa in Hypoxic Mucus , 2014, Infection and Immunity.

[19]  E. Hoffman,et al.  Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis , 2014, Science.

[20]  A. Fialho,et al.  Characterization of BCAM0224, a Multifunctional Trimeric Autotransporter from the Human Pathogen Burkholderia cenocepacia , 2014, Journal of bacteriology.

[21]  J. Klockgether,et al.  Developing an international Pseudomonas aeruginosa reference panel , 2013, MicrobiologyOpen.

[22]  C. Heiner,et al.  Draft Genome Sequences of Burkholderia cenocepacia ET12 Lineage Strains K56-2 and BC7 , 2013, Genome Announcements.

[23]  A. Confer,et al.  The OmpA family of proteins: roles in bacterial pathogenesis and immunity. , 2013, Veterinary microbiology.

[24]  Susan Murray,et al.  Decade-long bacterial community dynamics in cystic fibrosis airways , 2012, Proceedings of the National Academy of Sciences.

[25]  S. Molin,et al.  Phenotypes of Non-Attached Pseudomonas aeruginosa Aggregates Resemble Surface Attached Biofilm , 2011, PloS one.

[26]  N. Høiby,et al.  Pseudomonas aeruginosa biofilms in cystic fibrosis. , 2010, Future microbiology.

[27]  S. McClean,et al.  Invasion of Burkholderia cepacia complex isolates into lung epithelial cells involves glycolipid receptors. , 2010, Microbial pathogenesis.

[28]  P. Dřevínek,et al.  Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  S. Sousa,et al.  Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species , 2010, Applied Microbiology and Biotechnology.

[30]  H. Nelis,et al.  In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria. , 2009, The Journal of antimicrobial chemotherapy.

[31]  N. Høiby,et al.  Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  Raymond Lo,et al.  The Burkholderia Genome Database: facilitating flexible queries and comparative analyses , 2008, Bioinform..

[33]  Jonathan J. Dennis,et al.  Development of Galleria mellonella as an Alternative Infection Model for the Burkholderia cepacia Complex , 2008, Infection and Immunity.

[34]  Stephen G. J. Smith,et al.  A molecular Swiss army knife: OmpA structure, function and expression. , 2007, FEMS microbiology letters.

[35]  L. Tamm,et al.  Electrostatic couplings in OmpA ion-channel gating suggest a mechanism for pore opening , 2006, Nature chemical biology.

[36]  A. Torres,et al.  Outer Membrane Protein A of Escherichia coli O157:H7 Stimulates Dendritic Cell Activation , 2006, Infection and Immunity.

[37]  Amos Bairoch,et al.  The PROSITE database , 2005, Nucleic Acids Res..

[38]  Joanna B. Goldberg,et al.  The multifarious, multireplicon Burkholderia cepacia complex , 2005, Nature Reviews Microbiology.

[39]  S. Sousa,et al.  Studies on the Involvement of the Exopolysaccharide Produced by Cystic Fibrosis-Associated Isolates of the Burkholderia cepacia Complex in Biofilm Formation and in Persistence of Respiratory Infections , 2004, Journal of Clinical Microbiology.

[40]  P. Vandamme,et al.  Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. , 2002, The Journal of antimicrobial chemotherapy.

[41]  G. Novelli,et al.  Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting , 2002, Gene Therapy.

[42]  Gerald B. Pier,et al.  Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.

[43]  J. Lyczak,et al.  Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. , 2000, Microbes and infection.

[44]  C. Mohr,et al.  Invasion and Intracellular Survival ofBurkholderia cepacia , 2000, Infection and Immunity.

[45]  J. Engel,et al.  Pili Binding to Asialo-GM1 on Epithelial Cells Can Mediate Cytotoxicity or Bacterial Internalization byPseudomonas aeruginosa , 1999, Infection and Immunity.

[46]  J. Costerton,et al.  Bacterial biofilms: a common cause of persistent infections. , 1999, Science.

[47]  C. Schmid,et al.  Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. , 1998, The New England journal of medicine.

[48]  G. Pier,et al.  Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro , 1995, Infection and immunity.

[49]  M. Corey,et al.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.

[50]  OUP accepted manuscript , 2022, Nucleic Acids Research.

[51]  M. Amaral,et al.  New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. , 2015, Pharmacology & therapeutics.

[52]  J. Bhatt,et al.  Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. , 2014, The Cochrane database of systematic reviews.